Trial Profile
An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Cevostamab (Primary) ; Steroids; Tocilizumab
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Genentech
- 12 Dec 2023 Results of integrative analysis of peripheral blood (PB) and bone marrow aspirate (BMA) samples collected at baseline from patients in this study to understand the heterogeneity of patients with RRMM and potential correlations with clinical outcome, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (N=310, At data cut-off (March 1, 2023)) assessing whether responders in the GO39775 study demonstrated evidence of immune reconstitution (IR) while on cevostamab therapy, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 15 Jun 2023 Results (At cut-off (August 22, 2022, n= 75 ) presented at the 28th Congress of the European Haematology Association